CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
Kidney Transplantation, Kidney Diseases, Kidney Failure
About this trial
This is an interventional prevention trial for Kidney Transplantation focused on measuring Kidney Transplantation, Kidney Disease, Kidney Failure, Graft Rejection
Eligibility Criteria
Inclusion Criteria: Kidney transplant recipients under the care of the West London Renal and Transplant Centre Exclusion Criteria: Patients who are unable to give written informed consent Simultaneous kidney/pancreas transplant recipients Non-heart beating deceased donor transplant recipients Patients who would not be offered Campath-1H induction under our current protocol (patients with previous malignancy or with previous exposure to cytotoxic or antiproliferative agents)
Sites / Locations
- West London Renal and Transplant Centre, 4th Floor Ham House, Hammersmith Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Campath-Tacrolimus
Daclizumab-Tacrolimus-Mycophenolate
Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy
Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy